,,,

Ningning Lu1,2, Shugui Sheng3, Yiqi Xiong1,2

  • 1Interventional Therapy Center for Oncology, Beijing You'an Hospital, Capital Medical University, Beijing, China.

Frontiers in immunology
|September 24, 2024
PubMed
概括

这项研究开发了一种名谱,用于预测肝细胞癌 (HCC) 患者在切除后出现高系统性免疫炎症指数 (SII) 的复发. 该模型准确地识别了高风险的无复发生存 (RFS) 患者.

相关概念视频